Barinthus Biotherapeutics PLC BRNS
$0.62 $0.01 (1.54%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
BRNS Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Barinthus Biotherapeutics PLC is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Barinthus Biotherapeutics PLC. Stock Analysis BRNS
United States Health Care Nano Cap Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 14 full-time employees. The company went IPO on 2021-04-30. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. The company is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The firm's pipeline also includes VTP-850, VTP-500 and VTP-400.
Barinthus Biotherapeutics PLC (BRNS) Chart
Financial Metrics & Statements of Barinthus Biotherapeutics PLC (BRNS)
FAQ's for Barinthus Biotherapeutics PLC (BRNS)
- As of August 2026, Barinthus Biotherapeutics PLC BRNS is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Barinthus Biotherapeutics PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Barinthus Biotherapeutics PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Barinthus Biotherapeutics PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Barinthus Biotherapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Barinthus Biotherapeutics PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Barinthus Biotherapeutics PLC (BRNS)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
